漢達生技 https://validator.w3.org/feed/docs/rss2.html Material Information- Announcement of the newly appointed Chief Business Officer 重大訊息-公告本公司新任商務長 Material Information- Announcement of the Board’s Resolution to release the non-competition restriction on managerial officers 重大訊息-本公司董事會通過解除經理人競業禁止之限制案 Material Information- Announcement of the Board’s Resolution to redeem and cancel treasury shares for a capital reduction and the record date 重大訊息-公告本公司董事會決議註銷庫藏股暨訂定減資基準日 Material Information- Announcement on behalf of Handa Pharma, Inc. Increase captial to Handa Oncology, LLC 重大訊息-代重要子公司Handa Pharma,Inc.公告100%投資Handa Oncology, LLC Material Information- Announcement of the Board of Directors approved the consolidated financial statements for 2026 Q2. 重大訊息-公告本公司董事會通過115年第二季合併財務報告 Material Information- The Company was invited to attend the in-person and virtual institutional investor conference hosted by First Securities 重大訊息-本公司受邀參加第一金證券舉辦之實體暨線上法人說明會 法說會資訊 Material Information- The Company has been required by TPEx to announce the financial data according 誠信經營 獨立董事與內部稽核主管及會計師之溝通情形 HND-039 HND-039 Phyrago® 重大訊息-本公司因近期股價價格異常，應櫃買中心要求公布相關資訊，俾便投資人暸解 Material Information- Announcement of the Company’s Ex-Dividend Record Date and Related Matters 重大訊息-公告本公司訂定除息基準日相關事宜 重大訊息-代子公司 Handa Oncology, LLC 公告治療癌症之505(b)(2) 新藥 HND-039 OMCAZIO 取得美國 FDA 暫時性許可(Tentative Approval, TA) HND-027 Phyrago ® Material Information- Correction to Handa Pharmaceuticals, Inc., and on behalf of the subsidiary, regarding the 505(b)(2) new formulation drug HND-039 patent infringement lawsuit 重大訊息-更正公告本公司及代子公司Handa Pharma, Inc.及Handa Oncology, LLC公告505(b)(2)新藥HND-039美國專利訴訟案之相關文書案號 Material Information- Announces Handa Pharmaceuticals, Inc., and on behalf of the subsidiary, regarding the 505(b)(2) new formulation drug HND-039 patent infringement lawsuit 重大訊息-公告本公司及代子公司Handa Pharma, Inc.及Handa Oncology, LLC公告505(b)(2)新藥HND-039美國專利訴訟案 Financials 財務資訊 Shareholders’ Services HOME 股東專區 Company Profile 公司基本資料 Material Information- Announcement of the 2026 Annual Shareholders’Meeting Approved the Proposal to release the Non-Competition Restrictions on Directors Material Information- Announces on Behalf Handa Oncology, LLC, regarding the 505 (b)(2) new formulation drug HND-039 OMCAZIO receives U.S. FDA Tentative Approval (TA) 重大訊息-公告本公司115年股東常會通過解除董事競業禁止之限制 Material Information- Announcement of the Important Resolutions of the Company’s 2026 Annual Shareholders’ Meeting 重大訊息-公告本公司115年股東常會重要決議事項 Material Information- Announcement of the Completion of the Company’s Treasury Share Buyback 重大訊息-公告本公司買回庫藏股執行完畢 Material Information- Announcement of the expected date of the Board Meeting to approve 2026 Q2 Financial Report on August 6, 2026 Material Information- Announcement that the cumulative number of treasury shares repurchased by the Company has reached 2% of the total issued shares 重大訊息-公告本公司買回庫藏股數量累積達公司已發行股份總額百分之二事宜 重大訊息-公告本公司115年第二季財務報告董事會預計召開日期為115年8月6日 Material Information- Announcement of the Completion of Registration for the Cancellation of Restricted Employee Shares Issued by the Company 重大訊息-公告本公司限制員工權利新股註銷完成變更登記事宜 首頁